Cohance Lifesciences Share Price | Cohance Lifesciences Stock Screener
COHANCE
Pharmaceuticals
Share Price NSE
₹418.55
▼
-1.35 (-0.32%)
Share Price BSE
₹418.50
▼
-2.00 (-0.48%)
As of May 22, 2026, the Cohance Lifesciences share price (NSE: COHANCE) is ₹418.55 on NSE and ₹418.50 on BSE, down 0.32% from the previous close, with shares trading between ₹416.60 and ₹424.00, and a 52-week range of ₹279.90–₹1,108.80.
Check COHANCE yearly price range for the annual price range and momentum.
Use the Cohance Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Cohance Lifesciences Market Cap
₹16,190.24 Cr.
COHANCE P/E Ratio (TTM)
113.57
Cohance Lifesciences P/B Ratio
4.35
EPS (TTM)
₹4.69
Dividend Yield
-
Debt to Equity
0.09
COHANCE 52 Week High
₹1108.80
Cohance Lifesciences 52 Week Low
₹279.90
Operating Margin
13.00%
Profit Margin
1.30%
COHANCE Revenue (TTM)
₹617.00
EBITDA
₹80.00
Net Income
₹8.00
Total Assets
₹5,730.00
Total Equity
₹3,911.00
Cohance Lifesciences Share Price Chart
Screen Cohance Lifesciences share price with an interactive chart. Analyse COHANCE price trends and volatility across different timeframes.
Cohance Lifesciences Company Profile - Fundamental Screener
Screen Cohance Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for COHANCE shares.
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Vivek Sharma
ISIN
INE03QK01018
Website
https://www.suvenpharm.com
Cohance Lifesciences Balance Sheet Screener
Screen COHANCE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total Assets | 5,730 | 3,032 | 2,254 | 1,966 | 1,830 | 1,475 | 1,173 | 783 |
| Current Assets | 1,796 | 889 | 1,263 | 1,011 | 1,128 | 565 | 392 | 390 |
| Fixed Assets | 2,263 | 1,713 | 670 | 663 | 534 | 441 | 357 | 271 |
| Liabilities | ||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1,050 | 826 | 97 | 72 | 92 | 74 | 128 | 35 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||
| Total Equity | 3,911 | 1,841 | 2,051 | 1,735 | 1,527 | 1,181 | 845 | 590 |
| Share Capital | 38 | 26 | 26 | 26 | 26 | 26 | 13 | 13 |
| Reserves & Surplus | 3,873 | 1,671 | 2,025 | 1,710 | 1,502 | 1,155 | 832 | 578 |
Cohance Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen Cohance Lifesciences income statement and profit fundamentals.
Analyze COHANCE quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Cohance Lifesciences share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 617 | 853 | 564 | 571 | 551 | 270 | 508 | 620 | 698 | 381 | 358 | 251 | 234 | 381 | 350 |
| Expenses | 537 | 627 | 445 | 435 | 454 | 180 | 363 | 398 | 439 | 198 | 181 | 133 | 154 | 207 | 188 |
| EBITDA | 80 | 226 | 118 | 137 | 97 | 90 | 145 | 222 | 259 | 183 | 178 | 118 | 80 | 174 | 162 |
| Operating Profit % | 13.00% | 25.00% | 19.00% | 22.00% | 17.00% | 29.00% | 26.00% | 34.00% | 35.00% | 47.00% | 48.00% | 42.00% | 30.00% | 43.00% | 45.00% |
| Depreciation | 51 | 54 | 45 | 44 | 47 | 17 | 31 | 38 | 44 | 12 | 13 | 12 | 13 | 10 | 12 |
| Interest | 9 | 10 | 10 | 9 | 9 | 2 | 10 | 10 | 11 | 5 | 1 | 1 | 2 | 2 | 2 |
| Profit Before Tax | 20 | 161 | 63 | 84 | 41 | 71 | 103 | 174 | 205 | 166 | 164 | 105 | 66 | 161 | 149 |
| Tax | 12 | 44 | 16 | 17 | 12 | 18 | 28 | 36 | 51 | 42 | 43 | 26 | 19 | 70 | 41 |
| Net Profit | 8 | 117 | 46 | 66 | 29 | 53 | 75 | 138 | 154 | 124 | 121 | 80 | 47 | 92 | 108 |
| EPS | 0.51 | 3.16 | 1.28 | 1.94 | 0.96 | 2.10 | 1.98 | 3.63 | 4.02 | 4.87 | 4.74 | 3.13 | 1.84 | 3.60 | 4.22 |
Cohance Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen COHANCE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
| Operating Activities | 288 | 359 | 457 | 330 | 383 | 407 | 50 |
| Investing Activities | -253 | -362 | -195 | -136 | -311 | -414 | -66 |
| Financing Activities | 3 | -14 | -242 | -156 | -76 | 7 | 26 |
| Net Cash Flow | 38 | -18 | 20 | 37 | -5 | 1 | 11 |
Cohance Lifesciences Shareholding Pattern Screener
See Cohance Lifesciences shareholding pattern with promoter, FII, and DII holdings.
Check Cohance Lifesciences promoter holding and ownership changes for COHANCE on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-May | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 57.49% | 50.10% | 66.41% | 66.41% | 57.49% | 57.49% | 50.10% | 50.10% |
| FII Holding | 5.59% | 11.05% | 7.38% | 7.23% | 6.51% | 6.02% | 9.54% | 9.80% |
| DII Holding | 21.79% | 16.60% | 11.02% | 11.40% | 20.82% | 21.57% | 17.24% | 17.42% |
| Govt Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 7.04% | 9.68% | 6.63% | 6.40% | 6.42% | 6.76% | 10.51% | 10.08% |
| Other Holding | 8.08% | 12.55% | 8.55% | 8.55% | 8.75% | 8.16% | 12.59% | 12.59% |
| Shareholder Count | 85,230 | 86,325 | 88,658 | 80,910 | 75,284 | 81,877 | 68,932 | 65,777 |
Cohance Lifesciences Share Dividend Screener - Share Yield Analysis
Check Cohance Lifesciences dividend history with payout and yield data.
View Cohance Lifesciences dividend details including ex-dates and amounts for COHANCE stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹6.00 | 0.89% |
| 2022-March | ₹5.00 | 1.06% |
| 2021-March | ₹2.00 | 0.32% |
| 2020-March | ₹5.00 | 1.01% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Cohance Lifesciences Stock Index Membership
See which indices include Cohance Lifesciences stock.
Check COHANCE index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
BSE INDEX SMLSEL
NIFTY 500
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MNC
NIFTY MULTI MFG
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
NIFTY500 MULTICAP MOMENTUM QUALITY 50
Cohance Lifesciences Market Events Screener - Corporate Actions
Get Cohance Lifesciences corporate actions including splits, bonuses, and buybacks.
Check Cohance Lifesciences stock events that may affect COHANCE share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 1.00 /share | -3.05% | ||
| Bonus | 1:1 | 0.04% | ||
| Annual General Meeting | NA | -6.87% | ||
| Dividend | ₹ 5.00 /share | -3.05% | ||
| 2026-05-12 | 2026-05-12 | Quarterly Result Announcement | NA | 5.29% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | -33.96% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -20.48% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -5.19% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | -5.13% |
| 2025-05-07 | 2025-05-07 | Change Of Name | NA | 0.00% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -5.54% |
| 2024-11-28 | 2024-11-28 | Extraordinary General Meeting | NA | -0.62% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 4.44% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | 16.74% |
| 2023-12-15 | 2023-12-15 | Annual General Meeting | NA | 17.68% |
Cohance Lifesciences Competitors Screener - Peer Comparison
Screen COHANCE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Cohance Lifesciences Company Announcements - News Screener
Screen COHANCE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-24 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-22 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-05-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-21 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-21 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-20 | Outcome Of The Board Meeting | - |
| 2026-05-20 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-05-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-06 | Board Meeting Intimation for To Consider And Approve The Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended March 31 2026. | - |
| 2026-04-30 | Clarification On Movement In Price Of Equity Shares | - |
| 2026-04-29 | Clarification sought from Cohance Lifesciences Ltd | - |
| 2026-04-27 | Brief Profile Of Mr. Umang Vohra Chairman And Group CEO | - |
| 2026-04-27 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-04-27 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-04-13 | Clarification With Respect To Volume Movement | - |
| 2026-04-13 | Clarification sought from Cohance Lifesciences Ltd | - |
| 2026-04-02 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-30 | Appointment of Company Secretary and Compliance Officer | - |
| 2026-03-27 | Closure of Trading Window | - |